HLA B7 抗体 (PE)
(6 references)Our Local Distributor
北京 101111
Quick Overview for HLA B7 抗体 (PE) (ABIN1111104)
抗原
See all HLA B7 抗体适用
宿主
克隆类型
标记
应用范围
克隆位点
-
-
原理
- Anti-HLA-B7 PE
-
交叉反应 （详细）
- Human, Non-Human Primates
-
产品特性
- The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
-
纯化方法
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
-
免疫原
- Papain solubilised HLA-A2, B7
-
亚型
- IgG1
-
-
anti-HLA Class I B7 Alpha (HLA B7) antibody
HLA B7 适用: 人, Non-Human Primate FACS 宿主: 小鼠 Monoclonal BB7-1 unconjugated
anti-HLA Class I B7 Alpha (HLA B7) antibody (PE)HLA B7 适用: 人, Cynomolgus FACS 宿主: 小鼠 Monoclonal BB7-1 PE
anti-HLA Class I B7 Alpha (HLA B7) antibody (FITC)HLA B7 适用: 人, Cynomolgus FACS 宿主: 小鼠 Monoclonal BB7-1 FITC
anti-HLA Class I B7 Alpha (HLA B7) antibodyHLA B7 适用: 人, Cynomolgus FACS 宿主: 小鼠 Monoclonal BB7-1 unconjugated
anti-HLA Class I B7 Alpha (HLA B7) (N-Term) antibodyHLA B7 适用: 人 WB, EIA 宿主: 兔 Polyclonal unconjugated
-
-
应用备注
- Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 106 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
缓冲液
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
-
储存液
- Sodium azide
-
注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
注意事项
- Do not freeze,Protect from prolonged exposure to light
-
储存条件
- 4 °C
-
储存方法
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
-
: "Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).
: "Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS." in: Molecular & cellular proteomics : MCP, Vol. 4, Issue 12, pp. 1888-97, (2005) (PubMed).
: "Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP)." in: Clinical and experimental immunology, Vol. 128, Issue 3, pp. 525-31, (2002) (PubMed).
: "Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 10, pp. 2766-72, (1999) (PubMed).
: "Immunoradiometric assay for the rapid detection of HLA-B27." in: Immunology and cell biology, Vol. 66 ( Pt 3), pp. 215-9, (1991) (PubMed).
: "Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 86, Issue 7, pp. 2361-4, (1989) (PubMed).
-
: "Immunogenic HLA-B7-restricted peptides of hTRT." in: International immunology, Vol. 18, Issue 12, pp. 1707-18, (2006) (PubMed).
-
- HLA B7 (HLA Class I B7 Alpha (HLA B7))
-
别名
- HLA-B7
-
背景
- HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22 % of healthy Caucasian individuals.
-
基因ID
- 35
-
途径
- Human Leukocyte Antigen (HLA) in Adaptive Immune Response
抗原
-
